 Prevention of Mania and Maintenance Treatment in Bipolar Disorder (26 Minutes)
Faculty: By Charles L. Bowden, MD
This CME Expert Review PsychCast™ is jointly sponsored by the Mount Sinai School of Medicine and MBL Communications.
Release Date: April 30, 2010
Termination Date: April 30, 2012
Estimated time to complete this activity: 15 minutes
Medium: The content is delivered by PsychCast™ with a PDF or web-based Posttest
Acknowledgment of Commercial Support: Funding for this activity has been provided by an educational grant from Bristol-Myers Squibb
Activity Review Information: The activity content has been peer-reviewed and approved by M. Mehmet Haznedar, MD. Review Date: November 30, 2009.
Faculty Affiliation
Charles L. Bowden, MD, is clinical professor of psychiatry and pharmacology at the University of Texas Health Science Center in San Antonio.
CME Course Director James C.-Y. Chou, MD, is associate professor of psychiatry at Mount Sinai School of Medicine in New York City.
M. Mehmet Haznedar, MD, is assistant Professor of Psychiatry, Mount Sinai School of Medicine.
Faculty Disclosure Policy Statement
It is the policy of the Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.
Faculty Disclosure
Dr. Bowden is a consultant to Bristol-Myers Squibb, Pfizer, sanofi-aventis, and Schering; and receives grant support from Repligen. Dr. Bowden's article mentions off-label usage of valproate for maintenance treatment of bipolar disorder.
Dr. Chou has received honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, and Pfizer.
Dr. Haznedar reports no financial, academic, or other interest in any organization that may pose a conflict of interest.
Learning Objectives
At the completion of this activity, participants should be better able to:
•Design therapeutic interventions to manage symptoms of acute mania and mixed episodes using appropriate dosing, switching, and combination strategies
Target Audience: This activity is designed to meet the educational needs of psychiatrists.
Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Mount Sinai School of Medicine and MBL Communications, Inc. The Mount Sinai School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: The Mount Sinai School of Medicine designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclaimer: These are the opinions of the authors not of the sponsors or supporters. For more information, contact MBL Communications at cme@mblcommunications.com.
Minimum Hardware/Software Requirements
Macintosh: PowerPC processor, Mac OS 8.6, 9.0.4, 9.1, or Mac OS X, 64MB of RAM, 24MB of available hard-disk space, and Safari 1.x or 2.x.
Windows PC: Intel Pentium processor, Microsoft Windows 95 OSR 2.0, Windows 98 and 98 SE, Windows Millennium Edition, Windows NT 4.0 with Service Pack 5, Windows 2000, or Windows XP, 64MB of RAM, 24MB of available hard-disk space, and Internet Explorer 6.x and newer or Firefox 1.x and newer.
This CME Activity and Posttest information file is a PDF (Portable Document Format) document. To view this file, you will need Adobe Acrobat Reader, which is available free at www.adobe.com. Follow the instructions on that page to download and install the software.
Prevention of Mania and Maintenance Treatment in Bipolar Disorder
(26 Minutes)
Faculty: Charles L. Bowden, MD
Abstract
Bipolar disorder is a lifelong condition, which is diagnosed according to corroborative features such as family history, chronobiological sensitivities, treatment outcomes, longitudinal course, and patterns of recurrence. Each illness state is also classified as involving pure mania, hypomania, a mixed episode, a depressed phase, or euthymia. Mixed states are thought to comprise an important subgroup of syndromically ill individuals with bipolar disorder. Several dimensions of psychopathology, including thought-language problems, behavioral disturbances, mood symptoms, and chronobiological changes demand careful evaluation when considering the presentation of a patient with bipolar disorder. Once a comprehensive diagnostic assessment for acute or mixed mania has been completed, it is important to look at an evidence-based data set to guide treatment selection for mood stabilization. Pharmacotherapy is essential to its long-term management of bipolar disorder. Combination therapy, including at least one mood stabilizer, may be necessary to treat acute depression and mania and to further prevent both depressive and manic recurrences. The goal is to minimize frequency, duration, and severity of depressive and manic symptoms with a treatment regimen that is positioned to maximize treatment adherence and minimize side effects. Prevention of mania and maintenance treatment in bipolar disorder is largely routed in the decision to use monotherapy or combination therapy in the treatment regimen. Treatment must also include consideration of comorbidities such as anxiety, substance abuse, cardiovascular disease, and metabolic syndrome, which are pervasive in the bipolar disorder population.
In this Expert Review PsychCast, Charles L. Bowden, MD, reviews prevention of mania and maintenance treatment in bipolar disorder, specifically addressing the ability to weigh efficacy against adverse effects.
To receive credit for this activity: Listen to the PsychCast™, reflect on the material presented, and complete the online CME Posttest/Evaluation here or to submit the CME Posttest/Evaluation by mail or fax, download a PDF here. To obtain credit, you should score 70% or better. The estimated time to complete the PsychCast™ and the posttest and evaluation is 15 minutes. Successful completion of the posttest and evaluation will allow you to claim credit and print a certificate.
Early submission of this posttest is encouraged: please submit by April 30, 2012 to be eligible for credit. If you have any questions, please e-mail cme@mblcommunications.com.
Read the extended CME supplement related to this PsychCast™ activity here
|
Subscribe |
Download |
|
|
|
|
